NCT05770687 SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
| NCT ID | NCT05770687 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kiyuk Chang |
| Condition | Myocardial Infarction |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-08-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-08-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.
Eligibility Criteria
Inclusion Criteria: * Acute myocardial infarction who were treated with percutaneous coronary intervention * Type 2 diabetes mellitus * Started SGLT2 inhibitors \<1 month before/after PCI Exclusion Criteria: * Type 1 diabetes mellitus * Insulin / GLP-1 analogue users * Previous users of SGLT2 inhibitors * Pregnancy
Contact & Investigator
Kiyuk Chang, MD, PhD
PRINCIPAL INVESTIGATOR
Seoul St. Mary's Hospital
Frequently Asked Questions
Who can join the NCT05770687 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05770687 currently recruiting?
Yes, NCT05770687 is actively recruiting participants. Contact the research team at kiyuk@catholic.ac.kr for enrollment information.
Where is the NCT05770687 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05770687 clinical trial?
NCT05770687 is sponsored by Kiyuk Chang. The principal investigator is Kiyuk Chang, MD, PhD at Seoul St. Mary's Hospital. The trial plans to enroll 1,000 participants.